AIM: To determine whether contrast-enhanced ultrasound (CEUS) can improve the precision of breast imaging reporting and data system (BI-RADS) categorization. METHODS: A total of 230 patients with 235 solid breast lesions classified as BI-RADS 4 on conventional ultrasound were evaluated. CEUS was performed within one week before core needle biopsy or surgical resection and a revised BI-RADS classification was assigned based on 10 CEUS imaging characteristics. Receiver operating characteristic curve analysis was then conducted to evaluate the diagnostic performance of CEUS-based BI-RADS assignment with pathological examination as reference criteria. RESULTS: The CEUS-based BI-RADS evaluation classified 116/235 (49.36%) lesions into category 3, 20 (8.51%), 13 (5.53%) and 12 (5.11%) lesions into categories 4A, 4B and 4C, respectively, and 74 (31.49%) into category 5. Selecting CEUS-based BI-RADS category 4A as an appropriate cut-off gave sensitivity and specificity values of 85.4% and 87.8%, respectively, for the diagnosis of malignant disease. The cancer-to-biopsy yield was 73.11% with CEUS-based BI-RADS 4A selected as the biopsy threshold compared with 40.85% otherwise, while the biopsy rate was only 42.13% compared with 100% otherwise. Overall, only 4.68% of invasive cancers were misdiagnosed. CONCLUSION: This pilot study suggests that evaluation of BI-RADS 4 breast lesions with CEUS results in reduced biopsy rates and increased cancer-to-biopsy yields.
AIM: To determine whether contrast-enhanced ultrasound (CEUS) can improve the precision of breast imaging reporting and data system (BI-RADS) categorization. METHODS: A total of 230 patients with 235 solid breast lesions classified as BI-RADS 4 on conventional ultrasound were evaluated. CEUS was performed within one week before core needle biopsy or surgical resection and a revised BI-RADS classification was assigned based on 10 CEUS imaging characteristics. Receiver operating characteristic curve analysis was then conducted to evaluate the diagnostic performance of CEUS-based BI-RADS assignment with pathological examination as reference criteria. RESULTS: The CEUS-based BI-RADS evaluation classified 116/235 (49.36%) lesions into category 3, 20 (8.51%), 13 (5.53%) and 12 (5.11%) lesions into categories 4A, 4B and 4C, respectively, and 74 (31.49%) into category 5. Selecting CEUS-based BI-RADS category 4A as an appropriate cut-off gave sensitivity and specificity values of 85.4% and 87.8%, respectively, for the diagnosis of malignant disease. The cancer-to-biopsy yield was 73.11% with CEUS-based BI-RADS 4A selected as the biopsy threshold compared with 40.85% otherwise, while the biopsy rate was only 42.13% compared with 100% otherwise. Overall, only 4.68% of invasive cancers were misdiagnosed. CONCLUSION: This pilot study suggests that evaluation of BI-RADS 4 breast lesions with CEUS results in reduced biopsy rates and increased cancer-to-biopsy yields.
Entities:
Keywords:
Biopsy; Breast imaging reporting and data system; Contrast-enhanced ultrasound; False positive biopsy
Authors: Karla Kerlikowske; Rebecca A Hubbard; Diana L Miglioretti; Berta M Geller; Bonnie C Yankaskas; Constance D Lehman; Stephen H Taplin; Edward A Sickles Journal: Ann Intern Med Date: 2011-10-18 Impact factor: 25.391
Authors: Heidi D Nelson; Kari Tyne; Arpana Naik; Christina Bougatsos; Benjamin K Chan; Linda Humphrey Journal: Ann Intern Med Date: 2009-11-17 Impact factor: 25.391
Authors: Rebecca Smith-Bindman; Philip W Chu; Diana L Miglioretti; Edward A Sickles; Roger Blanks; Rachel Ballard-Barbash; Janet K Bobo; Nancy C Lee; Matthew G Wallis; Julietta Patnick; Karla Kerlikowske Journal: JAMA Date: 2003-10-22 Impact factor: 56.272
Authors: Marcela G del Carmen; Kevin S Hughes; Elkan Halpern; Elizabeth Rafferty; Daniel Kopans; Yuri R Parisky; Armando Sardi; Lisa Esserman; Steven Rust; James Michaelson Journal: Cancer Date: 2003-08-01 Impact factor: 6.860